Has a single UPC action yet been stayed in view of a parallel EPO opposition? The court is very reluctant to be delayed by EPO opposition proceedings and remains patentee-friendly in its general approach.
READ MOREThe Patent Prosecution Highway (PPH) provides a mechanism for accelerating examination of a patent application at a second patent office, if examination work has already been conducted at a first patent office with whom a PPH agreement is in place. If claims of an application have been found acceptable by a first office (often the office of first filing), accelerated examination of a corresponding application at a second office may be requested. The PPH allows a second patent office to make use of relevant work already conducted by a first office when examining an application.
Haakon Thue Lie, IP Consultant in the Dehns Oslo office, shares his thoughts on high growth SMES, referring to new reports from IP Australia, an EUIPO/EPO report and several papers on collaboration, open innovation and IP management.
If one posed to most EUIPO practitioners the question: ‘what do Champagne, sherry, chocolate, yoghurt and rice have in common?’ they may not have a clue. The answer is they have all been protected under the English law of extended passing off.
Using passing off as a way of opposing a later trade mark has had something of a chequered history during the time the UK has been part of the EUIPO system. The use of extended passing off brings with it a further dimension in that the owner of the goodwill is one of many, who claims that there has been some damage as a result of a misrepresentation.
However, the Indo European Foods decision has turned a corner on the understanding of this form of protection and reliance on it.
For all IP practitioners, ranging from those that draft patent specifications, through in house lawyers and outside counsel, that deal with pharmaceuticals, this case is a ‘must read’. For ‘big pharma’ itself, it is a welcome relief following (then) Arnold J’s first instance judgement on how claims with functional and structural limitations should be considered when attacked on the basis of insufficiency, in particular, a lack of plausibility and undue burden.
With the coronavirus pandemic affecting billions of people and millions of businesses around the world throughout 2020 and 2021, there can scarcely have been a more important time for scientific innovation in the race to understand, treat and protect people from the virus. In late spring 2021, we sent a survey to our clients looking at how intellectual property (IP) intensive firms have responded and adapted to the global COVID-19 pandemic throughout 2020, into 2021 and beyond. This report is based on the responses we received, which highlighted the resilience of innovative and IP intensive businesses during the pandemic, and their bright future.
A Supplementary Protection Certificate (SPC) is a form of intellectual property that can extend the protection of patented active ingredients present in pharmaceutical or plant protection products by up to five years.
On 14 November 2018 the UK Supreme Court (SC) handed down its decision in Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis, which includes a majority judgment and interesting dissenting ones.
European patent law differs in some significant aspects from the law in other countries, in particular the United States. This note sets out some important features of European patent law to remember when preparing patent applications for Europe.
If you have identified an interesting opportunity for a research or development collaboration and are discussing a potential agreement, then Intellectual Property (IP) is one of the key factors that will need your consideration. This article provides clear, practical guidance on how to approach the key IP issues that can arise before, during and after such collaborations.
European patent law differs in some significant aspects from the law in others countries, in particular the United States. Our briefing note on “European Practice for Overseas Attorneys” discusses some more general issues to bear in mind when drafting. This note provides some more detailed tips on drafting European patent applications so that some common problems can be avoided.
Subscribe here for updates on IP news, events and webinars.
|